or Try an Advanced Search...

    Technical Analysis for DCPH - Deciphera Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    A 25.45 0.04% 0.01
    DCPH closed up 0.04 percent on Wednesday, May 15, 2024, on 49 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Very Strong Up Up Flat
    Historical DCPH trend table...
    Date Alert Name Type % Chg
    Crossed Above 20 DMA Bullish 0.67%
    Crossed Above 50 DMA Bullish 0.67%
    MACD Bullish Centerline Cross Bullish 0.67%
    MACD Bullish Signal Line Cross Bullish 0.67%
    New 52 Week Closing High Bullish 0.67%
    Pocket Pivot Bullish Swing Setup 0.67%
    Volume Surge Other 0.67%
    NR7 Range Contraction 0.67%
    Narrow Range Bar Range Contraction 0.67%
    New 52 Week High Strength 0.67%
    Older End-of-Day Signals for DCPH ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakout 16 days ago
    Possible NR7 16 days ago
    Possible Inside Day 16 days ago
    Possible Pocket Pivot 16 days ago
    2x Volume Pace 16 days ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    DCPH Chart by TradingView
    Basic chart:

    Profile

    Deciphera Pharmaceuticals, Inc. Description

    Deciphera Pharmaceuticals, LLC is a United-States based clinical-stage biopharmaceutical company. The Company provides treatment for cancer patients. The Company focuses on developing tumor-targeted and immuno-targeted kinase inhibitors. Its switch control inhibitor platform is engaged in producing kinase inhibitors with distinct profiles and anti-cancer effects. Its tumor-targeting therapies include DCC-2618. DCC-2618 is a pan-KIT and PDGFR alpha kinase switch control inhibitor in clinical development for the treatment of KIT and/or Platelet-derived growth factor receptor alpha-driven cancers, including gastrointestinal stromal tumors, glioblastoma multiforme and systemic mastocytosis. Its Immuno-Targeted Therapies include DCC-3014 and Rebastinib. DCC-3014 is a potent and highly-selective immunokinase inhibitor targeting colony stimulating factor receptor 1 (CSF1R). Rebastinib is a TIE2 inhibitor targeting TIE2 expressing macrophages. Rebastinib is in the clinical development stage.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Cancer Immune System Drugs Clinical Development Cancer Treatment Gastrointestinal Antineoplastic Drugs Blastoma Glioblastoma Protein Kinase Inhibitor Tyrosine Kinase Receptors Targeted Therapy Glioblastoma Multiforme Platelet Mastocytosis Systemic Mastocytosis Gastrointestinal Stromal Tumor Gastrointestinal Stromal Tumors Treatment For Cancer

    Is DCPH a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 10 Here's What Key Metrics Tell Us About Deciphera Pharmaceuticals (DCPH) Q1 Earnings
    May 10 Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Misses Revenue Estimates
    May 5 Wall Street Breakfast: The Week Ahead
    May 3 The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine
    May 2 Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More
    Apr 30 ONO to acquire Deciphera Pharmaceuticals in $2.4B deal
    Apr 30 Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion
    Apr 29 Why Is Cancer Focused Deciphera Pharmaceuticals Stock Skyrocketing On Monday?
    Apr 29 Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Apr 29 Ono Pharmaceutical acquires cancer-focused biopharma Deciphera for $2.4bn
    See more DCPH news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 25.55
    52 Week Low 9.9
    Average Volume 1,994,192
    200-Day Moving Average 14.84
    50-Day Moving Average 17.95
    20-Day Moving Average 21.57
    10-Day Moving Average 25.39
    Average True Range 0.61
    RSI (14) 85.92
    ADX 51.51
    +DI 58.80
    -DI 9.12
    Chandelier Exit (Long, 3 ATRs) 23.73
    Chandelier Exit (Short, 3 ATRs) 15.82
    Upper Bollinger Bands 31.93
    Lower Bollinger Band 11.21
    Percent B (%b) 0.69
    BandWidth 96.05
    MACD Line 2.61
    MACD Signal Line 2.45
    MACD Histogram 0.1595
    Fundamentals Value
    Market Cap 2.06 Billion
    Num Shares 80.8 Million
    EPS -2.29
    Price-to-Earnings (P/E) Ratio -11.11
    Price-to-Sales 7.78
    Price-to-Book 3.62
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 25.51
    Resistance 3 (R3) 25.51 25.50 25.50
    Resistance 2 (R2) 25.50 25.48 25.50 25.50
    Resistance 1 (R1) 25.47 25.47 25.47 25.47 25.49
    Pivot Point 25.46 25.46 25.45 25.46 25.46
    Support 1 (S1) 25.43 25.44 25.43 25.43 25.41
    Support 2 (S2) 25.42 25.43 25.42 25.40
    Support 3 (S3) 25.39 25.42 25.40
    Support 4 (S4) 25.39